Search Results - "Carlton, Kevin"

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults by Gaudinski, Martin R, Coates, Emily E, Houser, Katherine V, Chen, Grace L, Yamshchikov, Galina, Saunders, Jamie G, Holman, LaSonji A, Gordon, Ingelise, Plummer, Sarah, Hendel, Cynthia S, Conan-Cibotti, Michelle, Lorenzo, Margarita Gomez, Sitar, Sandra, Carlton, Kevin, Laurencot, Carolyn, Bailer, Robert T, Narpala, Sandeep, McDermott, Adrian B, Namboodiri, Aryan M, Pandey, Janardan P, Schwartz, Richard M, Hu, Zonghui, Koup, Richard A, Capparelli, Edmund, Graham, Barney S, Mascola, John R, Ledgerwood, Julie E

“…VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being…”
Get full text

Mosaic quadrivalent influenza vaccine single nanoparticle characterization by Yang, Rong Sylvie, Traver, Maria, Barefoot, Nathan, Stephens, Tyler, Alabanza, Casper, Manzella-Lapeira, Javier, Zou, Guozhang, Wolff, Jeremy, Li, Yile, Resto, Melissa, Shadrick, William, Yang, Yanhong, Ivleva, Vera B., Tsybovsky, Yaroslav, Carlton, Kevin, Brzostowski, Joseph, Gall, Jason G., Lei, Q. Paula

“…Recent work by our laboratory and others indicates that co-display of multiple antigens on protein-based nanoparticles may be key to induce cross-reactive…”
Get full text

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design by Kwon, Young D, Georgiev, Ivelin S, Ofek, Gilad, Zhang, Baoshan, Asokan, Mangaiarkarasi, Bailer, Robert T, Bao, Amy, Caruso, William, Chen, Xuejun, Choe, Misook, Druz, Aliaksandr, Ko, Sung-Youl, Louder, Mark K, McKee, Krisha, O'Dell, Sijy, Pegu, Amarendra, Rudicell, Rebecca S, Shi, Wei, Wang, Keyun, Yang, Yongping, Alger, Mandy, Bender, Michael F, Carlton, Kevin, Cooper, Jonathan W, Blinn, Julie, Eudailey, Joshua, Lloyd, Krissey, Parks, Robert, Alam, S Munir, Haynes, Barton F, Padte, Neal N, Yu, Jian, Ho, David D, Huang, Jinghe, Connors, Mark, Schwartz, Richard M, Mascola, John R, Kwong, Peter D

“…Extraordinary antibodies capable of near pan-neutralization of HIV-1 have been identified. One of the broadest is antibody 10E8, which recognizes the…”
Get full text

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency by Cai, Cindy X., Doria-Rose, Nicole A., Schneck, Nicole A., Ivleva, Vera B., Tippett, Brad, Shadrick, William R., O’Connell, Sarah, Cooper, Jonathan W., Schneiderman, Zachary, Zhang, Baoshan, Gowetski, Daniel B., Blackstock, Daniel, Demirji, Jacob, Lin, Bob C., Gorman, Jason, Liu, Tracy, Li, Yile, McDermott, Adrian B., Kwong, Peter D., Carlton, Kevin, Gall, Jason G., Lei, Q. Paula

“…CAP256V2LS, a broadly neutralizing monoclonal antibody (bNAb), is being pursued as a promising drug for HIV-1 prevention. The total level of tyrosine- O…”
Get full text

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial by Mahomed, Sharana, Garrett, Nigel, Karim, Quarraisha A, Zuma, Nonhlanhla Y, Capparelli, Edmund, Baxter, Cheryl, Gengiah, Tanuja, Archary, Derseree, Samsunder, Natasha, Rose, Nicole D, Moore, Penny, Williamson, Carolyn, Barouch, Dan H, Fast, Patricia E, Pozzetto, Bruno, Hankins, Catherine, Carlton, Kevin, Ledgerwood, Julie, Morris, Lynn, Mascola, John, Abdool Karim, Salim

“…IntroductionNew HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to…”
Get full text

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life by Zhang, Baoshan, Gollapudi, Deepika, Gorman, Jason, O’Dell, Sijy, Damron, Leland F., McKee, Krisha, Asokan, Mangaiarkarasi, Yang, Eun Sung, Pegu, Amarendra, Lin, Bob C., Chao, Cara W., Chen, Xuejun, Gama, Lucio, Ivleva, Vera B., Law, William H., Liu, Cuiping, Louder, Mark K., Schmidt, Stephen D., Shen, Chen-Hsiang, Shi, Wei, Stein, Judith A., Seaman, Michael S., McDermott, Adrian B., Carlton, Kevin, Mascola, John R., Kwong, Peter D., Lei, Q. Paula, Doria-Rose, Nicole A.

“…The broadly neutralizing antibody (bNAb) CAP256-VRC26.25 has exceptional potency against HIV-1 and has been considered for clinical use. During the…”
Get full text

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency by Zhang, Baoshan, Gorman, Jason, Kwon, Young D, Pegu, Amarendra, Chao, Cara W, Liu, Tracy, Asokan, Mangaiarkarasi, Bender, Michael F, Bylund, Tatsiana, Damron, Leland, Gollapudi, Deepika, Lei, Paula, Li, Yile, Liu, Cuiping, Louder, Mark K, McKee, Krisha, Olia, Adam S, Rawi, Reda, Schön, Arne, Wang, Shuishu, Yang, Eun Sung, Yang, Yongping, Carlton, Kevin, Doria-Rose, Nicole A, Shapiro, Lawrence, Seaman, Michael S, Mascola, John R, Kwong, Peter D

“…Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency,…”
Get full text

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention by Kwon, Young D, Asokan, Mangaiarkarasi, Gorman, Jason, Zhang, Baoshan, Liu, Qingbo, Louder, Mark K, Lin, Bob C, McKee, Krisha, Pegu, Amarendra, Verardi, Raffaello, Yang, Eun Sung, Program, Vrc Production, Carlton, Kevin, Doria-Rose, Nicole A, Lusso, Paolo, Mascola, John R, Kwong, Peter D

“…Passive transfer of broadly neutralizing antibodies is showing promise in the treatment and prevention of HIV-1. One class of antibodies, the VRC01 class,…”
Get full text

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial by Mahomed, Sharana, Garrett, Nigel, Potloane, Disebo, Sikazwe, Izukanji T, Capparelli, Edmund, Harkoo, Ishana, Gengiah, Tanuja Narayansamy, Zuma, Nonhlanhla Yende, Osman, Farzana, Mansoor, Leila, Archary, Derseree, Myeni, Nqobile, Radebe, Precious, Samsunder, Natasha, Doria-Rose, Nicole, Carlton, Kevin, Gama, Lucio, Koup, Richard A, Narpala, Sandeep, Serebryannyy, Leonid, Moore, Penny, Williamson, Carolyn, Pozzetto, Bruno, Hankins, Catherine, Morris, Lynn, Karim, Quarraisha Abdool, Abdool Karim, Salim

“…Women-controlled HIV prevention technologies that overcome adherence challenges of available daily oral pre-exposure prophylaxis and give women a choice of…”
Get full text

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial by Houser, Katherine V., Gaudinski, Martin R., Happe, Myra, Narpala, Sandeep, Verardi, Raffaello, Sarfo, Edward K., Corrigan, Angela R., Wu, Richard, Rothwell, Ro Shauna, Novik, Laura, Hendel, Cynthia S., Gordon, Ingelise J., Berkowitz, Nina M., Cartagena, Cora Trelles, Widge, Alicia T., Coates, Emily E., Strom, Larisa, Hickman, Somia, Conan-Cibotti, Michelle, Vazquez, Sandra, Trofymenko, Olga, Plummer, Sarah, Stein, Judy, Case, Christopher L., Nason, Martha, Biju, Andrea, Parchment, Danealle K., Changela, Anita, Cheng, Cheng, Duan, Hongying, Geng, Hui, Teng, I-Ting, Zhou, Tongqing, O'Connell, Sarah, Barry, Chris, Carlton, Kevin, Gall, Jason G., Flach, Britta, Doria-Rose, Nicole A., Graham, Barney S., Koup, Richard A., McDermott, Adrian B., Mascola, John R., Kwong, Peter D., Ledgerwood, Julie E.

“…Advances in therapeutic drugs have increased life-expectancies for HIV-infected individuals, but the need for an effective vaccine remains. We assessed safety…”
Get full text

Current strategic thinking for the development of a trivalent alphavirus vaccine for human use by Wolfe, Daniel N, Heppner, D Gray, Gardner, Shea N, Jaing, Crystal, Dupuy, Lesley C, Schmaljohn, Connie S, Carlton, Kevin

“…Vaccinations against the encephalitic alphaviruses (western, eastern, and Venezuelan equine encephalitis virus) are of significant interest to biological…”
Get full text

Prospective study of posttreatment changes in the temporomandibular joint by Carlton, Kevin L., Nanda, Ram S.

“…The purpose of this follow-up prospective longitudinal study was to determine what changes occurred in the condyle/fossa relationship after treatment…”
Get full text

The HALO system—a light weight portable imaging system by Routley, Nathan R., Carlton, Kevin J.

“…This paper describes the development of a prototype portable magnetic resonance imaging (MRI) device with anticipated application in material science and…”
Get full text

A Monoclonal Antibody for Malaria Prevention by Gaudinski, Martin R, Berkowitz, Nina M, Idris, Azza H, Coates, Emily E, Holman, LaSonji A, Mendoza, Floreliz, Gordon, Ingelise J, Plummer, Sarah H, Trofymenko, Olga, Hu, Zonghui, Campos Chagas, Andrezza, O’Connell, Sarah, Basappa, Manjula, Douek, Naomi, Narpala, Sandeep R, Barry, Christopher R, Widge, Alicia T, Hicks, Renunda, Awan, Seemal F, Wu, Richard L, Hickman, Somia, Wycuff, Diane, Stein, Judy A, Case, Christopher, Evans, Brian P, Carlton, Kevin, Gall, Jason G, Vazquez, Sandra, Flach, Britta, Chen, Grace L, Francica, Joseph R, Flynn, Barbara J, Kisalu, Neville K, Capparelli, Edmund V, McDermott, Adrian, Mascola, John R, Ledgerwood, Julie E, Seder, Robert A

“…Malaria remains a cause of substantial global morbidity and mortality. In this report, an engineered monoclonal antibody showed protection against malaria…”
Get full text

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study by Gaudinski, Martin R, Coates, Emily E, Novik, Laura, Widge, Alicia, Houser, Katherine V, Burch, Eugeania, Holman, LaSonji A, Gordon, Ingelise J, Chen, Grace L, Carter, Cristina, Nason, Martha, Sitar, Sandra, Yamshchikov, Galina, Berkowitz, Nina, Andrews, Charla, Vazquez, Sandra, Laurencot, Carolyn, Misasi, John, Arnold, Frank, Carlton, Kevin, Lawlor, Heather, Gall, Jason, Bailer, Robert T, McDermott, Adrian, Capparelli, Edmund, Koup, Richard A, Mascola, John R, Graham, Barney S, Sullivan, Nancy J, Ledgerwood, Julie E, Hendel, Cynthia Starr, Plummer, Sarah H., Costner, Pamela, Saunders, Jamie, Mendoza, Floreliz, Eshun, Aba Mensima, Casazza, Joseph, Ola, Abidemi, Whalen, William, Wang, Xiaolin, Cunningham, Jennifer, Vasilenko, Olga, Boyd, Catina R., Trofymenko, Olga, Burgos Florez, Maria Claudia, Hickman, Somia, Rothwell, Ro Shauna, Pittman, Iris R, Le, Lam Ngan, Larkin, Brenda D, Cox, Josephine H, Apte, Preeti J, Hicks, Renunda T, Trelles Cartagena, Cora, Williams, Pernell V, Requilman, LaShawn, Nguyen, Thuy, Tran, Colin, Vazquez, Sandra, Conan-Cibotti, Michelle, Stein, Judy, Beresnev, Tatiana

“…mAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques…”
Get full text

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali by Kayentao, Kassoum, Ongoiba, Aissata, Preston, Anne C., Healy, Sara A., Doumbo, Safiatou, Doumtabe, Didier, Traore, Abdrahamane, Traore, Hamadi, Djiguiba, Adama, Li, Shanping, Peterson, Mary E., Telscher, Shinyi, Idris, Azza H., Kisalu, Neville K., Carlton, Kevin, Serebryannyy, Leonid, Narpala, Sandeep, McDermott, Adrian B., Gaudinski, Martin, Traore, Siriman, Cisse, Hamidou, Keita, Mamadou, Skinner, Jeff, Hu, Zonghui, Zéguimé, Amatigué, Ouattara, Adama, Doucoure, M’Bouye, Dolo, Amagana, Djimdé, Abdoulaye, Traore, Boubacar, Seder, Robert A., Crompton, Peter D.

“…In this phase 2 trial in Mali, an antimalarial monoclonal antibody (CIS43LS) at a dose of 40 mg per kilogram was approximately 88% effective at preventing P…”
Get full text

Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial by Chen, Grace L, Coates, Emily E, Plummer, Sarah H, Carter, Cristina A, Berkowitz, Nina, Conan-Cibotti, Michelle, Cox, Josephine H, Beck, Allison, O’Callahan, Mark, Andrews, Charla, Gordon, Ingelise J, Larkin, Brenda, Lampley, Rebecca, Kaltovich, Florence, Gall, Jason, Carlton, Kevin, Mendy, Jason, Haney, Doug, May, Jeanine, Bray, Amy, Bailer, Robert T, Dowd, Kimberly A, Brockett, Brittanie, Gordon, David, Koup, Richard A, Schwartz, Richard, Mascola, John R, Graham, Barney S, Pierson, Theodore C, Donastorg, Yeycy, Rosario, Nicolas, Pape, Jean William, Hoen, Bruno, Cabié, André, Diaz, Clemente, Ledgerwood, Julie E

“…IMPORTANCE: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. OBJECTIVE: To…”
Get full text

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention by Mahomed, Sharana, Garrett, Nigel, Capparelli, Edmund V, Osman, Farzana, Harkoo, Ishana, Yende-Zuma, Nonhlanhla, Gengiah, Tanuja N, Archary, Derseree, Samsunder, Natasha, Baxter, Cheryl, Mkhize, Nonhlanhla N, Modise, Tandile, Carlton, Kevin, McDermott, Adrian, Moore, Penny L, Karim, Quarraisha Abdool, Barouch, Dan H, Fast, Patricia E, Mascola, John R, Ledgerwood, Julie E, Morris, Lynn, Abdool Karim, Salim S

“…Abstract Background Effective, long-acting prevention approaches are needed to reduce human immunodeficiency virus (HIV) incidence. We evaluated the safety and…”
Get full text

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial by Lyke, Kirsten E, Berry, Andrea A, Mason, Kaitlin, Idris, Azza H, O'Callahan, Mark, Happe, Myra, Strom, Larisa, Berkowitz, Nina M, Guech, Mercy, Hu, Zonghui, Castro, Mike, Basappa, Manjula, Wang, Lu, Low, Kwang, Holman, LaSonji A, Mendoza, Floreliz, Gordon, Ingelise J, Plummer, Sarah H, Trofymenko, Olga, Strauss, Kathleen S, Joshi, Sudhaunshu, Shrestha, Biraj, Adams, Matthew, Chagas, Andrezza Campos, Murphy, Jittawadee R, Stein, Judy, Hickman, Somia, McDougal, Andrew, Lin, Bob, Narpala, Sandeep R, Vazquez, Sandra, Serebryannyy, Leonid, McDermott, Adrian, Gaudinski, Martin R, Capparelli, Edmund V, Coates, Emily E, Wu, Richard L, Ledgerwood, Julie E, Dropulic, Lesia K, Seder, Robert A, Young, Cheryl, Boyce, Colleen, Winkler, Jennifer, Holian, Susan, Greenberg, Nancy, George, Shirley, Kwon, Alyson, Dorsey, Brenda, Da Costa, Ana Raquel, Witt, William, Grays, Daryl, Gapasin, Arren, Bernal, Paula, Floyd, Jeffrey, Goldstein, Eric, Howe, Leslie, Lee, Myounghee, Marron, Jennifer, Brooks, Kelly, Turek, Lisa, Farley, Patricia, Frels, Shantel, Booth, Delores, Gall, Jason, Carlton, Kevin, Albright, Gabriela, Amharref, Nadia, Atallah, Kandace, Banappagari, Sashikanth, Bastani, Niutish, Blackstock, Daniel, Boonyaratanakornkit, Bobby, Carey, Elizabeth, Charlton, Adam, Chaudhuri, Rajoshi, Caringal, Alegria M., Chen, Mingzhong, Chen, Peifeng, Cheng, Wei, Gowetski, Daniel, Gulla, Krishana, Hastings, Erica, Horwitz, Joe, Ivleva, Vera, Kordella, Dan, Kueltzo, Lisa A., Lagler, Sara, Le, Matt, Lee, James, Lei, Paula, Li, Yile, Nagy, Attila, Patel, Aakash, Runsewe, Peyi, Shadrick, Will, Shetty, Shamitha, Wang, Hairong, Webber, Calvin, Vejzagic, Farah, Yang, Yoo-Jung

“…Human monoclonal antibodies might offer an important new approach to reduce malaria morbidity and mortality. In the first two parts of a three-part clinical…”
Get full text

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial by Coates, Emily E, Edupuganti, Srilatha, Chen, Grace L, Happe, Myra, Strom, Larisa, Widge, Alicia, Florez, Maria Burgos, Cox, Josephine H, Gordon, Ingelise, Plummer, Sarah, Ola, Abidemi, Yamshchikov, Galina, Andrews, Charla, Curate-Ingram, Sharon, Morgan, Patricia, Nagar, Shashi, Collins, Matthew H, Bray, Amy, Nguyen, Thuy, Stein, Judy, Case, Christopher L, Kaltovich, Florence, Wycuff, Diane, Liang, C Jason, Carlton, Kevin, Vazquez, Sandra, Mascola, John R, Ledgerwood, Julie E

“…Western (WEEV), eastern (EEEV), and Venezuelan (VEEV) equine encephalitis viruses are mosquito-borne pathogens classified as potential biological warfare…”
Get full text